Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions.

Aspirin [acetylsalicylic acid (ASA)], along with its analgesic-antipyretic uses, is now also being considered for cardiovascular protection and treatments in cancer and human immunodeficiency virus infection. Although many of ASA's pharmacological actions are related to its ability to inhibit prostaglandin and thromboxane biosynthesis, some of its beneficial therapeutic effects are not completely understood. Here, ASA triggered transcellular biosynthesis of a previously unrecognized class of eicosanoids during coincubations of human umbilical vein endothelial cells (HUVEC) and neutrophils [polymorphonuclear leukocytes (PMN)]. These eicosanoids were generated with ASA but not by indomethacin, salicylate, or dexamethasone. Formation was enhanced by cytokines (interleukin 1 beta) that induced the appearance of prostaglandin G/H synthase 2 (PGHS-2) but not 15-lipoxygenase, which initiates their biosynthesis from arachidonic acid in HUVEC. Costimulation of HUVEC/PMN by either thrombin plus the chemotactic peptide fMet-Leu-Phe or phorbol 12-myristate 13-acetate or ionophore A23187 leads to the production of these eicosanoids from endogenous sources. Four of these eicosanoids were also produced when PMN were exposed to 15R-HETE [(15R)-15-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid] and an agonist. Physical methods showed that the class consists of four tetraene-containing products from arachidonic acid that proved to be 15R-epimers of lipoxins. Two of these compounds (III and IV) were potent inhibitors of leukotriene B4-mediated PMN adhesion to HUVEC, with compound IV [(5S,6R,15R)-5,6,15-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoi c acid; 15-epilipoxin A4] active in the nanomolar range. These results demonstrate that ASA evokes a unique class of eicosanoids formed by acetylated PGHS-2 and 5-lipoxygenase interactions, which may contribute to the therapeutic impact of this drug. Moreover, they provide an example of a drug's ability to pirate endogenous biosynthetic mechanisms to trigger new mediators.

[1]  J. Morrow,et al.  Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. , 1994, The Journal of biological chemistry.

[2]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[3]  T. Carlos,et al.  Leukocyte-endothelial adhesion molecules. , 1994, Blood.

[4]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[5]  C. Ji,et al.  Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. , 1994, The Journal of biological chemistry.

[6]  A. Ristimäki,et al.  Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. , 1994, The Journal of biological chemistry.

[7]  C. Serhan.  Lipoxin biosynthesis and its impact in inflammatory and vascular events. , 1994, Biochimica et biophysica acta.

[8]  B. Spur,et al.  Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet‐activating factor and N‐formyl‐L‐methionyl‐L‐leucyl‐L‐phenylalanine , 1994, Allergy.

[9]  J. Mancini,et al.  Mutation of serine‐516 in human prostaglandin G/H synthase‐2 to methionine or aspirin acetylation of this residue stimulates 15‐R‐HETE synthesis , 1994, FEBS letters.

[10]  R. Everson,et al.  Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study , 1994, Epidemiology.

[11]  J. Falgueyret,et al.  Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. , 1994, Molecular pharmacology.

[12]  A. Marcus,et al.  Vascular transcellular signaling. , 1993, Journal of lipid research.

[13]  J. Drazen,et al.  Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. , 1993, The Journal of clinical investigation.

[14]  C. Serhan,et al.  Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. , 1993, The Journal of clinical investigation.

[15]  C. Serhan,et al.  Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. , 1993, Biochemistry.

[16]  David A Jones,et al.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. , 1993, The Journal of biological chemistry.

[17]  D. Dewitt,et al.  Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. , 1993, The Journal of biological chemistry.

[18]  M. Holtzman,et al.  Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. , 1992, The Journal of biological chemistry.

[19]  T. Hla,et al.  Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Serhan,et al.  Adhesion promotes transcellular leukotriene biosynthesis during neutrophil-glomerular endothelial cell interactions: inhibition by antibodies against CD18 and L-selectin. , 1992, Biochemical and biophysical research communications.

[21]  C. Serhan,et al.  Angioplasty Triggers Intracoronary Leukotrienes and Lipoxin A4: Impact of Aspirin Therapy , 1992, Circulation.

[22]  D. Steinhilber,et al.  On the expression and regulation of 5-lipoxygenase in human lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Spur,et al.  Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. , 1989, Clinical science.

[24]  J. Haeggström,et al.  Human endothelial cells stimulate leukotriene synthesis and convert granulocyte released leukotriene A4 into leukotrienes B4, C4, D4 and E4. , 1988, European journal of biochemistry.

[25]  J. Falck,et al.  Absolute configuration of the hydroxyeicosatetraenoic acids (HETEs) formed during catalytic oxygenation of arachidonic acid by microsomal cytochrome P-450. , 1986, Biochemical and biophysical research communications.

[26]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[27]  G. Hunninghake,et al.  Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. , 1994, The Journal of clinical investigation.

[28]  S. Dahlén,et al.  Lipoxins inhibit microvascular inflammatory actions of leukotriene B4. , 1991, Advances in experimental medicine and biology.

[29]  N. F. Cooper.  Prostaglandins, leukotrienes and lipoxins biochemistry, mechanism of action and clinical applications: Edited by J Martyn Bailey. pp 705. Plenum Press, New York and London. 1985.$95 ISBN 0‐306‐41980‐7 , 1987 .

[30]  J. M. Bailey,et al.  Prostaglandins, leukotrienes, and lipoxins : biochemistry, mechanism of action, and clinical applications , 1985 .

[31]  Nobelstiftelsen.  Les Prix Nobel : Nobel Prizes, presentations, biographies and lectures , 1982 .